TITLE

Service development free papers

PUB. DATE
April 2005
SOURCE
Gut;Apr2005 Supplement 2, Vol. 54, pA26
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
The article presents information on abstracts related to human biology. An abstract presents information on the financial constraints limiting the prescription of infliximab in Crohn's disease. Infliximab, a chimeric monoclonal antibody against TNF-α, has been licensed for use in Great Britain since 1997 for patients with Crohn's disease. The treatment is recommended for use in a specific group of patients with the disease, as outlined in the National Institute of Clinical Excellence guidelines published in 2002. It remains unclear whether there are any factors preventing or limiting gastroenterologists from prescribing infliximab in these patients. The aim was to identify the factors limiting the prescription of infliximab in patients with Crohn's disease and to determine any regional variations in the frequency of its prescription.
ACCESSION #
16567961

 

Related Articles

  • Spotlight on Infliximab in Crohn Disease and Rheumatoid Arthritis. Siddiqui, M Asif A; Scott, Lesley J // BioDrugs;2006, Vol. 20 Issue 1, p67 

    Infliximab (Remicade) is a chimeric monoclonal antibody against tumor necrosis factor (TNF)-α that has shown efficacy in Crohn disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with initial...

  • Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study. Tursi, A.; Elisei, W.; Picchio, M.; Zampaletta, C.; Pelecca, G.; Faggiani, R.; Brandimarte, G. // Techniques in Coloproctology;Nov2014, Vol. 18 Issue 11, p1041 

    Background: Endoscopic and clinical recurrence of Crohn's disease (CD) appears in up to 80 and 30 % of patients, respectively, 1 year after surgery. Both infliximab (IFX) and adalimumab (ADA) have been demonstrated to be effective in reducing the possibility of recurrence after surgery, but...

  • Clinical Pharmacokinetics and Use of Infliximab. Klotz, Ulrich; Teml, Alexander; Schwab, Matthias // Clinical Pharmacokinetics;2007, Vol. 46 Issue 8, p645 

    Tumor necrosis factor-α (TNFα) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Infliximab, a chimeric (human-murine) monoclonal IgG1 anti-TNFα antibody, is used in the treatment of Crohn's disease (including fistulising disease) and rheumatoid arthritis (in...

  • Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Biancone, L.; Orlando, A.; Kohn, A.; Colombo, E.; Sostegni, R.; Angelucci, E.; Rizzello, F.; Castiglione, F.; Benazzato, I.; Papi, C.; Meucci, G.; Riegler, G.; Petruzziello, C.; Mocciaro, F.; Geremia, A.; Calabrese, E.; Cottone, M.; Pallone, F. // Gut;Feb2006, Vol. 55 Issue 2, p228 

    Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia....

  • Infliximab: A Review of its Use in Crohn’s Disease and Rheumatoid Arthritis. Siddiqui, M. Asif A.; Scott, Lesley J. // Drugs;2005, Vol. 65 Issue 15, p2179 

    Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor (TNF)-α that has shown efficacy in Crohn's disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with...

  • Adalimumab: In Crohn's Disease. Plosker, Greg L.; Lyseng-Williamson, Katherine A. // BioDrugs;2007, Vol. 21 Issue 2, p125 

    â–´ Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). â–´ The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal,...

  • A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. Gupta, Aditya K.; Skinner, Alayne R. // Journal of Cutaneous Medicine & Surgery;Mar/Apr2004, Vol. 8 Issue 2, p77 

    Background: Infliximab is a chimeric monoclonal antibody that binds specifically to human tumor necrosis factor-alpha (TNF-α), decreasing the effect of the cytokine in inflammatory diseases. Objective: The aim of this study was to review the efficacy and safety of infliximab in the treatment...

  • Erdheim–Chester disease: from palliative care to targeted treatment. Graziani, Giorgio; Podestà, Manuel A.; Cucchiari, David; Reggiani, Francesco; Ponticelli, Claudio // Clinical Kidney Journal;Aug2014, Vol. 7 Issue 4, p339 

    Erdheim–Chester disease (ECD) is a life-threatening multi-systemic non-Langerhans histiocytosis with cardiovascular complications as the leading cause of death. ECD affects the kidneys in up to 30% of cases, with fibrotic tissue deposition in the perirenal fat and renal hilum. Diagnosis...

  • Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Miyasaka, Nobuyuki; Takeuchi, Tsutomu; Eguchi, Katsumi // Modern Rheumatology (Springer Science & Business Media B.V.);Mar2005, Vol. 15 Issue 1, p4 

    Differences in ethnic backgrounds as well as in medical and socioeconomic status often affect both the efficacy and adverse effects of medications. Recent data suggest an increased risk of opportunistic infections, especially tuberculosis (TB), among rheumatoid arthritis (RA) patients receiving...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics